Daiichi Sankyo's Ezharmia Becomes First EZH1/2 Inhibitor for Blood Cancer

Daiichi Sankyo won approval in Japan for Ezharmia, a new therapy for the treatment of patients with relapsed or refractory adult T-cell leukemia/lymphoma (ATL).